Stopping Prostate Cancer Hormone Pill Drugs After One Year in Some Patients
Tests stopping androgen receptor drugs at 12 months in men with prostate cancer.
Key facts
- Who runs it
- Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)
- Where
- 's-Gravenhage, 'S-Gravenhage, Alkmaar, Almelo, Amersfoort, Amsterdam, Assen, Beverwijk, Deventer, Eindhoven, Emmen, Enschede, Goes, Groningen, Haarlem, Hilversum, Leeuwarden, Maastricht, Nieuwegein, Nijmegen, Roermond, Roosendaal, Rotterdam, and Venlo, NetherlandsSee the 28 sites
- Trial code
- Registry title
- Shortened 12 months duration of androgen receptor signalling agent in combination with androgen deprivation therapy in patients with low-volume castration-sensitive prostate cancer: a randomized Nationwide Study
- Status
- Recruiting
- Phase
- Phase 3
- People taking part
- 400 people, planned
- Started
- 2 Feb 2024
- Expected to end
- 1 Sept 2031
- Type of study
- Interventional
- Record updated
- 3 December 2025
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for men with prostate cancer that has spread a little (low-volume) and still responds to hormone therapy. It tests stopping the extra drug after 12 months.
- Age
- 18 years or older
- Sex
- Men only
- Disease stage
- Prostate adenocarcinoma with low-volume metastatic disease (M1a or M1b) found at diagnosis, confirmed by bone scan and CT or by PSMA-PET scan. Performance status ECOG 0, 1 or 2.
- Earlier treatment
- Hormone therapy (ADT) started within 6 weeks before joining. No other prior treatment for prostate cancer, such as other anti-androgens, CYP17 inhibitors, chemotherapy, immunotherapy or radiopharmaceutical agents.
Main reasons for not taking part
- Small cell, ductal or neuroendocrine prostate cancer
- Another cancer within 5 years, except squamous or basal cell skin cancer or non-invasive superficial bladder cancer
- History of seizures or medicines that lower the seizure threshold
- Any prostate cancer treatment other than ADT
- ADT started more than 6 weeks before joining
The registry criteria, word for word
Show all 12 criteriaShow less
Who can take part
- Male and ≥18 years of age
- Histological diagnosis of prostate adenocarcinoma
- Low-volume de novo metastatic disease (M1a or M1b) defined as anything other than fitting the criteria for high-volume metastatic disease, e.g., four or more bone lesions with one or more lesions in any body structure beyond the spine or pelvis, or visceral disease (non-nodal). This has been assessed by either bone scan and computed tomography (CT), or PSMA-PET scan. Low-volume disease has subsequently been confirmed by the local (multidisciplinary) team after consideration of the available imaging results as per the standard imaging protocol for the site
- ADT initiated within 6 weeks prior to inclusion
- Eastern Cooperative Oncology Group (ECOG) performance scale status of 0, 1 or 2
- Fit for treatment with apalutamide or enzalutamide according to treating physician
- Capable of understanding and complying with protocol requirements and able to understand and sign the informed consent form
Who cannot take part
- Any other prior treatment for prostate cancer other than ADT (e.g., other next generation anti-androgens or other CYP17 inhibitors, chemotherapy, immunotherapy, or radiopharmaceutical agents)
- ADT started more than 6 weeks before inclusion
- Other prior malignancy less than or equal to 5 years prior to randomization except for squamous or basal cell skin carcinoma or non-invasive superficial bladder cancer
- History of seizures or medications known to lower seizure threshold
- Pathological finding consistent with small cell, ductal or neuroendocrine carcinoma of the prostate
Where in Netherlands
- Haga Hospital's-Gravenhage, NetherlandsTaking people
- Haaglanden Medisch Centrum Stichting'S-Gravenhage, NetherlandsTaking people
- Noordwest Ziekenhuisgroep StichtingAlkmaar, NetherlandsTaking people
- Ziekenhuisgroep Twente StichtingAlmelo, NetherlandsTaking people
- Meander Medisch CentrumAmersfoort, NetherlandsTaking people
- Amsterdam UMCAmsterdam, NetherlandsTaking people
- Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis StichtingAmsterdam, NetherlandsTaking people
- Wilhelmina Ziekenhuis AssenAssen, NetherlandsTaking people
- Rode Kruis Ziekenhuis B.V.Beverwijk, NetherlandsTaking people
- Deventer ZiekenhuisDeventer, NetherlandsTaking people
- Catharina Ziekenhuis StichtingEindhoven, NetherlandsTaking people
- Stichting Treant ZiekenhuiszorgEmmen, NetherlandsTaking people
- Medisch Spectrum TwenteEnschede, NetherlandsTaking people
- ADRZGoes, NetherlandsTaking people
- Universitair Medisch Centrum GroningenGroningen, NetherlandsTaking people
- Spaarne Gasthuis StichtingHaarlem, NetherlandsTaking people
- TergooiziekenhuizenHilversum, NetherlandsTaking people
- Medisch Centrum Leeuwarden B.V.Leeuwarden, NetherlandsTaking people
- Universiteit MaastrichtMaastricht, NetherlandsTaking people
- Sint Antonius Ziekenhuis StichtingNieuwegein, NetherlandsTaking people
- Canisius-Wilhelmina HospitalNijmegen, NetherlandsTaking people
- Laurentius Ziekenhuis RoermondRoermond, NetherlandsTaking people
- Bravis ZiekenhuisRoosendaal, NetherlandsTaking people
- Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)Rotterdam, NetherlandsTaking people
- Ikazia ZiekenhuisRotterdam, NetherlandsTaking people
- Maasstad Ziekenhuis StichtingRotterdam, NetherlandsTaking people
- Sint Franciscus Vlietland Groep StichtingRotterdam, NetherlandsTaking people
- Stichting Viecuri Medisch Centrum voor Noord-LimburgVenlo, NetherlandsTaking people
About the trial
What the trial wants to find out
To evaluate whether the discontinuation of ARSIs 12 months after its initiation in low-volume metastatic castration-sensitive prostate cancer (mCSPC) patients with the possibility to restart treatment, is non-inferior to continued androgen receptor signaling inhibitors (ARSI), thereby sparing significant toxicity and costs
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorData and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).
- Official title
- Apa/Enza short study (Shortened 12 months duration of androgen receptor signalling agent in combination with androgen deprivation therapy in patients with low-volume metastatic castration-sensitive prostate cancer: a randomized nationwide trial
- Plain-language title
- Stopping Prostate Cancer Hormone Pill Drugs After One Year in Some PatientsGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 9 November 2026.
- Record updated
- 3 December 2025